The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Acadia Pharmaceuticals Inc shares valued at $90,000 were sold by Kihara James on May 16 ’25. At $22.50 per share, Kihara James sold 4,000 shares. The insider’s holdings dropped to 20,395 shares worth approximately $0.45 million following the completion of this transaction.
Also, Schneyer Mark C. sold 2,000 shares, netting a total of over 50,000 in proceeds. Following the sale of shares at $25.00 each, the insider now holds 62,130 shares.
Before that, Schneyer Mark C. had added 2,000 shares to its account. In a trade valued at $35,200, the Officer bought Acadia Pharmaceuticals Inc shares for $17.60 each.
As published in a research note from Deutsche Bank on May 21, 2025, Acadia Pharmaceuticals Inc [ACAD] has been rated up from a Hold to a Buy and the price target has been revised to $35. Analysts at Deutsche Bank started covering the stock with ‘”a Hold”‘ outlook in a report released in mid February. As of January 03, 2025, Guggenheim has decreased its “Buy” rating to a “Neutral” for ACAD.
Analyzing ACAD Stock Performance
During the last five days, there has been a surge of approximately 2.01%. Over the course of the year, Acadia Pharmaceuticals Inc shares have jumped approximately 21.47%. Shares of the company reached a 52-week high of $25.23 on 05/16/25 and a 52-week low of $13.40 on 04/09/25.
Support And Resistance Levels for Acadia Pharmaceuticals Inc (ACAD)
According to the 24-hour chart, there is a support level at 21.96, which, if violated, would cause prices to drop to 21.63. In the upper region, resistance lies at 22.62. The next price resistance is at 22.95. RSI (Relative Strength Index) is 76.37 on the 14-day chart, showing overbought technical sentiment.
